BioCentury
ARTICLE | Clinical News

LMTX: Phase III started

November 5, 2012 8:00 AM UTC

TauRx began a double-blind, placebo-controlled, international Phase III trial to evaluate twice-daily 100 mg oral LMTX for 18 months in about 500 patients with mild AD. LMTX is also in Phase II testin...